Stockwatch: Cardinal rule adherence – HALO slips but Shire shines
10:20 EDT 6 Aug 2012 | SCRIP
A cardinal rule in pharmaceutical drug development is that you never put the sales of an existing product at risk for a second generation product that may never exist. This is because you don't have to do much risk-adjustment for the sales of a....
Original Article: Stockwatch: Cardinal rule adherence – HALO slips but Shire shines
More From BioPortfolio on "Stockwatch: Cardinal rule adherence – HALO slips but Shire shines"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
